APELOA PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.11 CNY | +1.36% |
|
+8.12% | -8.32% |
| 04-17 | Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-10 | Apeloa Pharmaceutical Co.,Ltd Approves Cash Dividend for 2023 | CI |
| Sales 2024 * | 12.79B 1.77B 2.42B | Sales 2025 * | 14.78B 2.04B 2.8B | Capitalization | 16.5B 2.28B 3.13B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.23B 170M 233M | Net income 2025 * | 1.59B 220M 301M | EV / Sales 2024 * | 1.29 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.12 x |
| P/E ratio 2024 * |
13.5
x | P/E ratio 2025 * |
10.5
x | Employees | 7,208 |
| Yield 2024 * |
2.5% | Yield 2025 * |
3.37% | Free-Float | 47.03% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.36% | ||
| 1 week | +8.12% | ||
| Current month | +12.43% | ||
| 1 month | +12.43% | ||
| 3 months | +9.04% | ||
| 6 months | -16.36% | ||
| Current year | -8.32% |
1 week
13.24
14.31
1 month
12.3214.31
Current year
10.6615.64
1 year
10.6621.15
3 years
10.6641.87
5 years
8.6541.87
10 years
4.8641.87
| Managers | Title | Age | Since |
|---|---|---|---|
Xin Liang Xu
CEO | Chief Executive Officer | 55 | 20-01-01 |
Jin Hui Zhang
DFI | Director of Finance/CFO | 49 | 19-03-06 |
Fang Meng Zhu
CHM | Chairman | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wen Cai Xu
BRD | Director/Board Member | 58 | 05-04-14 |
Ling Chen
BRD | Director/Board Member | 58 | 20-04-07 |
Xiang Quan Ge
BRD | Director/Board Member | 50 | 23-04-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.44% | 2 M€ | -15.58% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 14.11 | +1.36% | 16,804,970 |
| 24-04-29 | 13.92 | +2.05% | 19,612,810 |
| 24-04-26 | 13.64 | +0.29% | 14,075,790 |
| 24-04-25 | 13.6 | +0.82% | 12,858,760 |
| 24-04-24 | 13.49 | -0.30% | 13,041,340 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Apeloa Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredient (API) intermediates, contract development and manufacturing organization (CDMO), preparations and others, as well as import and export trade. The Company operates three businesses. The API intermediates business mainly includes cephalosporin series, penicillin series, psychiatric series, cardiovascular and cerebrovascular series and veterinary API intermediates series. The CDMO business mainly includes research and development services, commercial human drug projects, commercial veterinary drug projects and other commercial products. The preparation business mainly includes anti-infective, cardiovascular and cerebrovascular, psychiatric and anti-tumor preparation products. The Company mainly operates its businesses in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-14
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.11
CNY
Average target price
17.75
CNY
Spread / Average Target
+25.80%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.32% | 2.28B | |
| +33.25% | 699B | |
| +28.59% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +14.81% | 236B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 149B |
- Stock Market
- Equities
- 000739 Stock
